Autoimmune Disease Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 168.0 billion
Estimated Base Value
2035 Forecast
US$ 303.7 billion
Projected Market Value
CAGR 2026–2035
6.1%
Compound Annual Growth
Largest Segment
Biologics
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
UCB
Emerging Players
Nimbus Therapeutics, Synthekine
Autoimmune Disease Therapeutics Market Overview
The Autoimmune Disease Therapeutics market addresses the need for pharmaceutical and biotechnology products designed to treat and manage conditions where the body's immune system attacks its own tissues. This market includes a range of therapeutic modalities, such as biologics, small molecule drugs, and corticosteroids, targeting various autoimmune disorders like rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, and multiple sclerosis. These therapeutics aim to modulate, suppress, or redirect the immune response to alleviate symptoms, prevent disease progression, and improve patient quality of life. Key buyers include hospitals, specialty pharmacies, and homecare providers, serving patients globally.
The Autoimmune Disease Therapeutics market is estimated at $168.0 Bn in 2025 and is forecast to reach $303.7 Bn in 2035, growing at a CAGR of 6.1% from 2025 to 2035. Market expansion is driven by the increasing global prevalence of autoimmune diseases, significant R&D investments in drug discovery, and improved diagnostic techniques enabling earlier detection. Conversely, high development costs, complex disease mechanisms, and stringent regulatory requirements pose restraints on market growth.
The market is segmented by Type (Biologics, Targeted Synthetic Disease Modifying Antirheumatic Drugs, etc.), Disease Indication (Rheumatoid Arthritis, Psoriasis, etc.), Mechanism of Action (Tumor Necrosis Factor Alpha Inhibitors, Interleukin Inhibitors, etc.), Route of Administration (Oral, Subcutaneous Injection, etc.), End-User (Hospitals & Clinics, Retail Pharmacies, etc.), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, etc.). Geographically, the market is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include UCB, argenx, Incyte, Alnylam Pharmaceuticals, Grifols, Kyowa Kirin, Genmab, Ipsen, BioMarin Pharmaceutical, Aurinia Pharmaceuticals, Apellis Pharmaceuticals, and Galapagos NV. The full report covers historical data and a forecast period through 2035, focusing on prescription pharmaceuticals and biologics for autoimmune conditions.
Market Definition & Overview
The Autoimmune Disease Therapeutics Market encompasses the pharmaceutical and biotechnology products developed, manufactured, and commercialized for the treatment and management of conditions where the body's immune system mistakenly attacks its own tissues. This market includes a diverse range of therapeutic modalities, such as biologics (e.g., monoclonal antibodies, fusion proteins), small molecule drugs (e.g., JAK inhibitors, conventional DMARDs), and corticosteroids, targeting various autoimmune disorders like rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, and multiple sclerosis. It covers drugs designed to modulate, suppress, or redirect the immune response to alleviate symptoms, prevent disease progression, and improve patient quality of life globally.
Scope
- Global market analysis across major geographies
- Segmented by drug class, disease indication, and route of administration
- Covers historical data from 2020 and forecast period through 2030
- Focuses on prescription pharmaceuticals and biologics for autoimmune conditions
Inclusions
- Biologic therapies, including monoclonal antibodies and fusion proteins
- Small molecule drugs, such as JAK inhibitors and traditional DMARDs
- Corticosteroids specifically prescribed for autoimmune conditions
- Immunosuppressant drugs used in autoimmune disease management
- Emerging cell and gene therapies targeting autoimmune pathways
- Marketed and late-stage pipeline therapeutics for autoimmune disorders
Exclusions
- Over-the-counter dietary supplements or vitamins
- Diagnostic tests or kits for autoimmune diseases
- Medical devices not directly integrated with drug delivery systems
- Vaccines for infectious diseases or allergies
- General healthcare services unrelated to therapeutic product sales
Market Size Forecast
Executive Summary
• The Autoimmune Disease Therapeutics market is valued at $168.0 Bn in 2025 and is forecast to reach $303.7 Bn by 2035, reflecting a robust CAGR of 6.1% as demand accelerates across every major segment and region over the ten-year outlook.
• Biologics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Asia Pacific is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intense competitive pressure from evolving biologics and biosimilars is driving strategic consolidations and partnerships, with major players aggressively acquiring innovative pipelines to maintain market dominance across core autoimmune indications globally.
• Expanding understanding of disease pathophysiology accelerates the development of highly targeted therapies and next-generation biologics, addressing significant unmet needs and catalyzing robust market expansion across diverse autoimmune conditions globally.
• Advancements in precision medicine, biomarker identification, and AI-driven drug discovery are revolutionizing therapeutic development, while adaptive regulatory pathways accelerate novel treatment approvals, particularly for severe or rare autoimmune diseases.
• Emerging markets offer substantial growth opportunities, yet access disparities and varied regulatory landscapes necessitate tailored market entry strategies, contrasting with mature regions where biosimilar penetration impacts established segments.
• Significant venture capital investment targets early-stage innovations, particularly in gene therapies and cell-based treatments, emphasizing robust R&D pipelines, while supply chain resilience remains a critical strategic priority for global distribution.
• The long-term outlook points to a paradigm shift towards disease modification and potential cures, requiring continuous innovation and strategic collaborations to overcome R&D complexities and ensure equitable patient access worldwide.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Autoimmune Disease Therapeutics Market was valued at $168.0 billion in the base year, reflecting a substantial existing market size.
Robust Growth Outlook
The market is projected for significant expansion, expected to reach $303.7 billion by the forecast year.
Strong CAGR
This growth trajectory represents a robust Compound Annual Growth Rate (CAGR) of 6.1% over the forecast period.
Innovation Fuels Expansion
Ongoing advancements and the introduction of novel biologic and targeted therapies are a key trend driving the market's substantial growth.
Rising Disease Burden
The increasing global prevalence and diagnosis of various autoimmune conditions significantly contribute to the sustained demand for therapeutics.
Leading Biologic Therapies
Biologic therapies are anticipated to remain a dominant segment within the market, driven by their proven efficacy and expanding indications across multiple autoimmune diseases.
Market Dynamics
Market Trends
- Shift towards targeted biologics dominates the market.
- Personalized medicine and precision therapies are gaining traction.
- Biosimilar adoption is increasing due to cost-effectiveness.
- Digital health solutions enhance patient monitoring and management.
Growth Drivers
- Increasing global prevalence of various autoimmune diseases.
- Significant R&D investments propel drug discovery and development.
- Improved diagnostic techniques enable earlier and accurate detection.
- Growing awareness and demand for advanced, effective treatments.
Restraints
- High development costs and complex disease mechanisms hinder innovation.
- Significant side effects and safety concerns limit patient uptake.
- Stringent regulatory requirements prolong market entry processes.
- Reimbursement challenges and high treatment costs restrict market access.
Opportunities
- Development of therapeutics for rare and underserved autoimmune conditions.
- Expansion into emerging economies with growing healthcare access.
- Researching novel drug targets and immunological pathways.
- Leveraging AI and machine learning for accelerated drug discovery.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | BiologicsTargeted Synthetic Disease Modifying Antirheumatic DrugsConventional Synthetic Disease Modifying Antirheumatic DrugsCorticosteroidsNonsteroidal Anti-Inflammatory DrugsImmunosuppressantsBiosimilarsCell & Gene Therapies |
| By Disease Indication | Rheumatoid ArthritisPsoriasisPsoriatic ArthritisInflammatory Bowel DiseaseMultiple SclerosisSystemic Lupus ErythematosusAnkylosing SpondylitisOthers |
| By Mechanism of Action | Tumor Necrosis Factor Alpha InhibitorsInterleukin InhibitorsJanus Kinase InhibitorsSelective T Cell Co-Stimulation ModulatorsB Cell DepletorsPhosphodiesterase 4 InhibitorsImmunosuppressantsCorticosteroids & Nsaids |
| By Route of Administration | OralSubcutaneous InjectionIntravenous InfusionTopical |
| By End-User | Hospitals & ClinicsRetail PharmaciesSpecialty PharmaciesHomecareAcademic & Research Institutions |
| By Distribution Channel | Hospital PharmaciesRetail PharmaciesOnline PharmaciesSpecialty PharmaciesDirect Distribution |
Regional Analysis
- North America leads the autoimmune disease therapeutics market due to its high disease prevalence, robust healthcare infrastructure, and substantial R&D funding. Strong reimbursement policies and the presence of major pharmaceutical innovators further solidify its dominant position globally.
- The Asia-Pacific region is projected to be the fastest-growing market, driven by increasing healthcare expenditure, rising awareness about autoimmune conditions, and improving diagnostic capabilities. Growing disposable incomes and a large patient pool contribute significantly to its rapid expansion.
- Europe is witnessing a notable trend towards the increasing adoption of biosimilars for autoimmune therapies, driven by cost-containment pressures and patent expirations of key biologics. This shift aims to enhance market access and affordability across various European countries.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates the market due to robust R&D, high healthcare expenditure, and a well-established pharmaceutical industry.
- High prevalence of autoimmune diseases and strong patient access to advanced therapies drive its leading position.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- An emerging market with increasing healthcare spending and improving access to advanced treatments, particularly in larger economies like Brazil and Mexico.
- However, economic volatility and healthcare infrastructure disparities remain challenges.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A significant market driven by advanced healthcare infrastructure, strong research capabilities, and a high volume of approved autoimmune disease treatments.
- Aging population and increasing disease awareness further contribute to its growth.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiences the fastest growth, fueled by rising disposable incomes, improving healthcare access, and a large patient pool across countries like China, Japan, and India.
- Increasing awareness and adoption of advanced therapeutics are key drivers.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Demonstrates strong growth potential, especially in the GCC countries with significant healthcare investments and a growing incidence of chronic diseases.
- Sub-Saharan Africa faces significant challenges but represents long-term opportunities for market expansion.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The largest market due to high disease prevalence, advanced healthcare infrastructure, and significant adoption of high-cost biologic therapies. Dominates R&D and new drug launches for autoimmune conditions. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | The largest pharmaceutical market in South America, driven by a large population, growing middle class, and increasing investment in healthcare infrastructure. It is experiencing a rise in autoimmune disease diagnoses and treatment access. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Europe's largest pharmaceutical market, characterized by high healthcare spending, a strong research base, and rapid adoption of innovative biologics for autoimmune diseases. Favorable reimbursement policies support market growth. |
| 4 | China | US$ XX.X Mn | XX.X% | The second-largest pharmaceutical market globally, with a vast patient population and rapidly increasing diagnosis rates for autoimmune diseases. Government reforms and expanding healthcare coverage are fueling significant market expansion. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | The largest healthcare market in the GCC, with high spending on specialized care and a growing prevalence of autoimmune diseases. Government initiatives like Vision 2030 are driving healthcare infrastructure development and access to advanced treatments. |
Countries Covered (25)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | UCB | XX.X% | Focus on developing innovative solutions for severe diseases, particularly in immunology and neurology, through patient-value driven R&D. | — | — | CimziaEvenityBriviact+1 |
| 2 | argenx | XX.X% | Develop differentiated antibody-based therapies for severe autoimmune diseases with high unmet medical needs by targeting FcRn. | — | — | VyvgartVyvgart Hytrulo |
| 3 | Incyte | XX.X% | Discover, develop, and commercialize novel therapeutics for oncology and inflammation/autoimmunity, leveraging their expertise in JAK inhibition. | — | — | JakafiOpzeluraPemazyre+1 |
| 4 | Alnylam Pharmaceuticals | XX.X% | Pioneer RNA interference (RNAi) therapeutics to treat rare genetic and other diseases, focusing on genetically validated targets. | — | — | OnpattroGivlaariAmvuttra+1 |
| 5 | Grifols | XX.X% | Global leader in plasma-derived medicines, focusing on collecting plasma, manufacturing products for rare and chronic diseases, and providing diagnostic solutions. | — | — | Gamunex-CXembifyAlbumin+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
UCB, argenx, Incyte, Alnylam Pharmaceuticals, Grifols, Kyowa Kirin, Genmab, Ipsen, BioMarin Pharmaceutical, Aurinia Pharmaceuticals, Apellis Pharmaceuticals, Galapagos NV, BridgeBio Pharma, Immunovant, Xencor, ACELYRIN, Ventyx Biosciences, Kezar Life Sciences, AnaptysBio, Connect Biopharma
The global Autoimmune Disease Therapeutics market features a competitive landscape led by UCB, argenx, Incyte, Alnylam Pharmaceuticals, Grifols, and Kyowa Kirin, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
UCB
argenx
Incyte
Alnylam Pharmaceuticals
Grifols
Kyowa Kirin
Genmab
Ipsen
BioMarin Pharmaceutical
Aurinia Pharmaceuticals
Apellis Pharmaceuticals
Galapagos NV
BridgeBio Pharma
Immunovant
Xencor
ACELYRIN
Ventyx Biosciences
Kezar Life Sciences
AnaptysBio
Connect Biopharma
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Amgen Completes Major Acquisition of Horizon Therapeutics
Amgen finalized its US$ XX.X acquisition of Horizon Therapeutics in October 2023, significantly bolstering its rare disease portfolio with key autoimmune assets like Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout.
Eli Lilly's Omvoh Gains EU Approval for Ulcerative Colitis
Following its US FDA approval in October 2023, Eli Lilly received European Commission approval in March 2024 for Omvoh (mirikizumab) to treat adults with moderate to severe active ulcerative colitis, introducing a new IL-23 inhibitor to the market.
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis
Bristol Myers Squibb secured FDA approval in September 2023 for Sotyktu (deucravacitinib) to treat active psoriatic arthritis, making it the first oral selective TYK2 inhibitor available for this indication after its prior approval for psoriasis.
Argenx Launches Subcutaneous Vyvgart Hytrulo for gMG
Argenx introduced Vyvgart Hytrulo, a new subcutaneous formulation of efgartigimod, in June 2023 after FDA approval for generalized myasthenia gravis, offering patients a more convenient, at-home treatment option compared to intravenous administration.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $168.0 Bn |
| Market Size (Forecast) | $303.7 Bn |
| CAGR | 6.1% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 25 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Autoimmune Disease Therapeutics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Autoimmune Disease Therapeutics market is estimated at $168.0 Bn in 2025.
The Autoimmune Disease Therapeutics market is forecast to grow at a CAGR of 6.1% from 2025 to 2035.
The market is segmented by Type, Disease Indication, Mechanism of Action, Route of Administration, End-User, and Distribution Channel. Key types include Biologics and Targeted Synthetic Disease Modifying Antirheumatic Drugs.
Leading companies include UCB, argenx, Incyte, Alnylam Pharmaceuticals, Grifols, Kyowa Kirin, Genmab, Ipsen, BioMarin Pharmaceutical, Aurinia Pharmaceuticals, Apellis Pharmaceuticals, and Galapagos NV.
The report covers global market analysis across major geographies, segmented by drug class, disease indication, and route of administration. It includes historical data and a forecast period through 2035, focusing on prescription pharmaceuticals and biologics for autoimmune conditions.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Alzheimer's Disease Therapeutics Market
$8.6 Bn in 2025 · 11.9% CAGR
Inflammatory Bowel Disease Therapeutics Market
$27.6 Bn in 2025 · 5.2% CAGR
Neurodegenerative Disease Therapeutics Market
$63.4 Bn in 2025 · 6.7% CAGR
Parkinson's Disease Therapeutics Market
$6.5 Bn in 2025 · 6.3% CAGR
Atopic Dermatitis Therapeutics Market
$18.7 Bn in 2025 · 8.4% CAGR
Computational Therapeutics Market
$600.0 Mn in 2025 · 18.6% CAGR
Epilepsy Therapeutics Market
$5.8 Bn in 2025 · 7.7% CAGR
Exosome Therapeutics Market
$186.1 Mn in 2025 · 28.6% CAGR